

Recommendations from York and Scarborough Medicines Commissioning Committee May 2020

	Drug name	Indication	Recommendation, rationale and place in therapy	RAG status	Potential full year cost impact
CCG commissioned Technology Appraisals					
1.	TA623: Patiomer for treating hyperkalaemia		<p>Patiomer is recommended as an option for treating hyperkalaemia in adults only if used:</p> <ul style="list-style-type: none"> • in emergency care for acute life-threatening hyperkalaemia alongside standard care or • for people with persistent hyperkalaemia and stages 3b to 5 chronic kidney disease or heart failure, if they: <ul style="list-style-type: none"> ○ have a confirmed serum potassium level of at least 6.0 mmol/litre and ○ are not taking, or are taking a reduced dosage of, a renin-angiotensin-aldosterone system (RAAS) inhibitor because of hyperkalaemia and ○ are not on dialysis. <p>Stop patiomer if RAAS inhibitors are no longer suitable. This recommendation is not intended to affect treatment with patiomer that was started in the NHS before this guidance was published</p>	AMBER Shared Care (RED until shared care in place)	<p>Deferred from Mar 2020 meeting</p> <p>Patiomer slightly cheaper than alternative Sodium zirconium cyclosilicate for same NICE TA approved indications.</p> <p>Agreed patiomer 1st line and sodium zirconium 2nd line when patiomer is ineffective or when dosing restrictions are not possible.</p>
NHSE commissioned Technology Appraisals – for noting					
2.	TA625: Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal)		NICE is unable to make a recommendation about the use in the NHS of recombinant human parathyroid hormone for treating hypoparathyroidism because Shire Pharmaceuticals (now part of Takeda) did not provide an evidence submission. The company has advised NICE that there is a clinical study being done in the UK, so there is insufficient evidence to provide a submission for this appraisal at this stage.	n/a	No cost impact to CCGs as NHS England commissioned.
3.	TA627: Lenalidomide with rituximab for previously treated follicular lymphoma		Lenalidomide with rituximab is recommended, within its marketing authorisation, as an option for previously treated follicular lymphoma (grade 1 to 3A) in adults. It is only recommended if the company provides lenalidomide according to the commercial arrangement.	RED	No cost impact to CCGs as NHS England commissioned.

Formulary applications or amendments/pathways/guidelines				
4.	Guideline on Using Ferric Maltol instead of intravenous iron treatments in Iron Deficiency	Approved and agreed use not just for use during Covid-19 pandemic (Note: has already been approved by Vale of York CCG Exec)	n/a	
5.	Apomorphine Shared Care Guideline	Approved updated version to include Dacepton® brand	n/a	No cost to CCGs expected as reflects current prescribing practice.
6.	PCSK pathway version 2	Approved with minor updates to existing guideline.	n/a	No cost to CCGs expected as reflects current prescribing practice.
7.	Length of Review Date for Shared Care Guidelines	Approved that going forward new shared care guidelines and existing shared care guidelines that come up for review should have a new review date of 3 years instead of 2 years unless important new information (e.g. safety information, change in national guidelines) becomes available.	n/a	